| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a7f82940e47ba7a1188f8e2ffca55e0f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2502-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-25
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-23
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5158 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0639
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0784
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| filingDate |
1993-03-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2000-04-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2afbcabb0f2f84a3286371abbc1b402b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_79843bcc7987f8a8fb5a11adab27476c |
| publicationDate |
2000-04-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-0633930-B1 |
| titleOfInvention |
In vitro generation of human dendritic cells |
| abstract |
A method is provided for generating human dendritic cells in vitro by treating CD34<+> cells with tumor necrosis factor- alpha and either interleukin-3 or GM-CSF. The invention also includes cellular compositions of dendritic cells produced by this method. Dendritic cells of the invention can be used widely as components in many diagnostic and therapeutic systems, including improved mixed lymphocyte reactions for assaying tissue rejection, adoptive immunotherapy of cancer, adoptive immunotherapy of HIV infections, and SCID-hu mice for human antibody production. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7977095-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9528088-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6867041-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6797514-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2251418-A1 |
| priorityDate |
1992-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |